These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 3528404)

  • 1. Analysis of a prospectively randomized comparison of doxorubicin versus 5-fluorouracil, doxorubicin, and BCNU in advanced gastric cancer: implications for future studies.
    Levi JA; Fox RM; Tattersall MH; Woods RL; Thomson D; Gill G
    J Clin Oncol; 1986 Sep; 4(9):1348-55. PubMed ID: 3528404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-fluorouracil, adriamycin, and BCNU (FAB) combination chemotherapy for advanced gastric cancer.
    Lopez M; Perno CF; Di Lauro L; Papaldo P
    Cancer Chemother Pharmacol; 1984; 12(3):194-7. PubMed ID: 6368030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.
    Kim NK; Park YS; Heo DS; Suh C; Kim SY; Park KC; Kang YK; Shin DB; Kim HT; Kim HJ
    Cancer; 1993 Jun; 71(12):3813-8. PubMed ID: 8508349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase III study of 5-FU and carmustine versus 5-FU, carmustine, and doxorubicin in advanced gastric cancer.
    Schnitzler G; Queisser W; Heim ME; König H; Katz R; Fritze D; Herrmann R; Arnold H; Henss H; Trux FA
    Cancer Treat Rep; 1986 Apr; 70(4):477-9. PubMed ID: 3516396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of advanced measurable gastric carcinoma with 5-fluorouracil, adriamycin, and BCNU.
    Lopez M; Di Lauro L; Papaldo P; Conti EM
    Oncology; 1986; 43(5):288-91. PubMed ID: 3763122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Eastern Cooperative Oncology Group evaluation of combinations of methyl-CCNU, mitomycin C, Adriamycin, and 5-fluorouracil in advanced measurable gastric cancer (EST 2277).
    Douglass HO; Lavin PT; Goudsmit A; Klaassen DJ; Paul AR
    J Clin Oncol; 1984 Dec; 2(12):1372-81. PubMed ID: 6439836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized comparison of 5-FU alone or combined with carmustine, doxorubicin, and mitomycin (BAFMi) in the treatment of advanced gastric cancer: a phase III trial of the Italian Clinical Research Oncology Group (GOIRC).
    De Lisi V; Cocconi G; Tonato M; Di Costanzo F; Leonardi F; Soldani M
    Cancer Treat Rep; 1986 Apr; 70(4):481-5. PubMed ID: 3516397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma.
    Gibson MK; Holcroft CA; Kvols LK; Haller D
    Oncologist; 2005 Feb; 10(2):132-7. PubMed ID: 15709215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-Fluorouracil versus a combination of BCNU, adriamycin, 5-FU and mitomycin C in advanced gastric cancer: a prospective randomized study of the Italian Clinical Research Oncology Group.
    De Lisi V; Cocconi G; Tonato M; Di Costanzo F; Leonardi F; Soldani M
    Recent Results Cancer Res; 1988; 110():212-8. PubMed ID: 3136519
    [No Abstract]   [Full Text] [Related]  

  • 10. Chemotherapy of advanced gastric carcinoma (stage IV): a randomized study of FAM versus 5-FU plus BCNU.
    Villar A; Asensio F; Candel M; Delgado F; Garcia J; Lledó S; Redón J; Roig JV; Sanchez A; Sanchis C
    Chemioterapia; 1987 Feb; 6(1):57-62. PubMed ID: 3103932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trials of 5-FU, doxorubicin, and cisplatin in advanced, measurable adenocarcinoma of the lung and stomach.
    Cazap EL; Gisselbrecht C; Smith FP; Estevez RA; Alvarez CA; Lagarde C; Hannois A; Ahmed S; Schein PS; Woolley PV
    Cancer Treat Rep; 1986 Jun; 70(6):781-3. PubMed ID: 3524826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An EORTC Gastrointestinal Group phase III evaluation of combinations of methyl-CCNU, 5-fluorouracil, and adriamycin in advanced gastric cancer.
    Lacave A; Wils J; Bleiberg H; Diaz-Rubio E; Duez N; Dalesio O
    J Clin Oncol; 1987 Sep; 5(9):1387-93. PubMed ID: 3305795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil.
    Kelsen D; Karpeh M; Schwartz G; Gerdes H; Lightdale C; Botet J; Lauers G; Klimstra D; Huang Y; Saltz L; Quan V; Brennan M
    J Clin Oncol; 1996 Jun; 14(6):1818-28. PubMed ID: 8656250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-Fluorouracil, epirubicin, and BCNU (FEB) in advanced measurable gastric cancer.
    Lopez M; Natali M; Di Lauro L; Tonini G; Carpano S; Vici P; Conti EM
    Am J Clin Oncol; 1990 Jun; 13(3):204-7. PubMed ID: 1693258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase III randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil and mitomycin C versus 5-fluorouracil alone in curatively resected gastric cancer.
    Chang HM; Jung KH; Kim TY; Kim WS; Yang HK; Lee KU; Choe KJ; Heo DS; Bang YJ; Kim NK
    Ann Oncol; 2002 Nov; 13(11):1779-85. PubMed ID: 12419751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An EORTC Gastrointestinal Group evaluation of the combination of sequential methotrexate and 5-fluorouracil, combined with adriamycin in advanced measurable gastric cancer.
    Wils J; Bleiberg H; Dalesio O; Blijham G; Mulder N; Planting A; Splinter T; Duez N
    J Clin Oncol; 1986 Dec; 4(12):1799-803. PubMed ID: 3783204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective comparison of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (modified FAM) combination chemotherapy versus palliative therapy in treatment of advanced gastric cancer.
    Park JO; Chung HC; Cho JY; Rha SY; You NC; Kim JH; Noh SH; Kim CB; Min JS; Kim BS; Roh JK
    Am J Clin Oncol; 1997 Oct; 20(5):484-9. PubMed ID: 9345333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group.
    Cullinan SA; Moertel CG; Wieand HS; O'Connell MJ; Poon MA; Krook JE; Mailliard JA; Tschetter LK
    J Clin Oncol; 1994 Feb; 12(2):412-6. PubMed ID: 8113849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group.
    Vanhoefer U; Rougier P; Wilke H; Ducreux MP; Lacave AJ; Van Cutsem E; Planker M; Santos JG; Piedbois P; Paillot B; Bodenstein H; Schmoll HJ; Bleiberg H; Nordlinger B; Couvreur ML; Baron B; Wils JA
    J Clin Oncol; 2000 Jul; 18(14):2648-57. PubMed ID: 10894863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. International Collaborative Cancer Group.
    Coombes RC; Schein PS; Chilvers CE; Wils J; Beretta G; Bliss JM; Rutten A; Amadori D; Cortes-Funes H; Villar-Grimalt A
    J Clin Oncol; 1990 Aug; 8(8):1362-9. PubMed ID: 2199622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.